One of the most problematic issues in investigations of the female sexual response is the limited availability of a reliable physiological measure of genital arousal. In men, penile tumescence and ...

Female sexual arousal disorder (FSAD) is a common disorder encountered in clinical practice, with self-reported arousal difficulties reported in up to 26% of American women. Various oral therapies for ...

FSAD is clinically analogous to erectile dysfunction in men. To date, there are no FDA-approved pharmacological treatments for FSAD; Daré’s Sildenafil Cream has the potential to receive the first FDA ...

New research sheds light on how to treat female sexual dysfunction. April 14, 2010— -- Researchers may be one step closer to a Viagra for women, given the results of a British study released ...

SAN DIEGO, March 24, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel ...

Daré Bioscience, in collaboration with Strategic Science & Technologies, announced plans for a Phase 3 clinical study of Sildenafil Cream, 3.6%, aimed at treating female sexual arousal disorder (FSAD) ...